nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2015-2-2-85-88nodgo-106Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL CASESКРАНИАЛЬНАЯ НЕЙРОПАТИЯ, ИНДУЦИРОВАННАЯ ПРИМЕНЕНИЕМ ВИНКРИСТИНА, У РЕБЕНКА С САРКОМОЙ ЮИНГАCRANIAL NEUROPATHY, INDUCED BY VINCRISTINE ADMINISTRATION AT A CHILD SUFFERING WITH EWING,S SARCOMAМалевичО. Б.MalevichO. B.olga.mal83@mail.ruФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России; Россия, 117198, Москва, ул. Саморы Машела, 1РоссияFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaRussian Federation201529052015228588Copyright © Малевич О.Б., 20152015Малевич О.Б.Malevich O.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/106

Лекарственная нейропатия – наиболее часто встречаемое осложнение со стороны нервной системы у детей, получающих терапию химиотерапевтическими агентами. Среди наиболее неблагоприятно действующих препаратов выделяют винкристин (ВНК), нейротоксичность которого зачастую ведет к редукции дозы или его полной отмене из используемого протокола лечения. Клиническая картина нейропатии, индуцированной ВНК, в большинстве случаев представлена поражением нервных волокон верхних и нижних конечностей с развитием симптоматики периферической полинейропатии. Более редко мишенью ВНК становятся аксоны черепно-мозговых нервов. Представленный клинический случай описывает наблюдение краниальной нейропатии, поражение глазодвигательного нерва, проявляющееся двусторонним птозом, у ребенка с саркомой Юинга, получающего лечение по протоколу СWS-2009.

The pharmaceutical neuropathy is the most often complication from the part of the nervous system at children, receiving the therapy with chemical therapeutic agents. Among most unfavorable substance vincristine (VNC) is highlighted, which neurotoxicity often causes the dose reduction or its full withdrawal from the used treatment protocol. The clinical pattern of the VNC induced neuropathy in most cases is represented by the lesion of nerve fibers of upper and lower extremities with the development of symptoms of the peripheral polyneuropathy. In more rare cases VNC causes the lesion of axons of cranial and brain nerves. The given clinical case describes the monitoring of the cranial neuropathy, the lesion of the oculomotor nerve, presented by bilateral ptosis at a child with Ewing,s sarcoma, treated by СWS-2009 protocol.

винкристиндетинейропатиясаркома ЮингатерапиянаблюдениепротоколнейротоксичностьопухольvincristinechildrenneuropathyEwings sarcomatreatmentobservationprotocolneurotoxicitytumorReferencesGursel O., Sari E., Atay A. A. et al. Vincristine-induced unilateral ptosisGursel O., Sari E., Atay A. A. et al. Vincristine-induced unilateral ptosisin a child. Pediatr Neurol 2009;41:461–3.in a child. Pediatr Neurol 2009;41:461–3.Talebian A., Mohammadzadeh M., Mirzadeh A. S. Vincristine-induced cranial neuropathy. Child Neurol 2014;8(1):66–8.Talebian A., Mohammadzadeh M., Mirzadeh A. S. Vincristine-induced cranial neuropathy. Child Neurol 2014;8(1):66–8.Tarlaci S. Vincristine-induced fatal neuropathy in non-Hodgkin,s lymphoma. Neurotoxicology 2008;29(4):748–9.Tarlaci S. Vincristine-induced fatal neuropathy in non-Hodgkin,s lymphoma. Neurotoxicology 2008;29(4):748–9.Toker E., Yenice O., Ogut M. S. Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS 2004;8:69–71.Toker E., Yenice O., Ogut M. S. Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS 2004;8:69–71.Dixit G., Dhingra A., Kaushal D. Vincristine induced cranial neuropathy. J Assoc Physicians India 2012;60:56–8.Dixit G., Dhingra A., Kaushal D. Vincristine induced cranial neuropathy. J Assoc Physicians India 2012;60:56–8.Shurin S. B., Rekate H. L., Annable W. Optic atrophy induced by vincristine. Pediatrics 1982;70(2):288–91.Shurin S. B., Rekate H. L., Annable W. Optic atrophy induced by vincristine. Pediatrics 1982;70(2):288–91.Jaggi A. S., Singh N. Mechanism in cancer-chemotherapeutic drug-induced peripheral neuropathy. Toxicology 2012; 291(1–3):1–9.Jaggi A. S., Singh N. Mechanism in cancer-chemotherapeutic drug-induced peripheral neuropathy. Toxicology 2012; 291(1–3):1–9.Gomber S., Dewan P., Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 2010;77:97–100.Gomber S., Dewan P., Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 2010;77:97–100.Lash S. C., Williams C. P., Marsh C. S. et al. Acute sixth-nerve palsy after vincristine therapy. J APOS 2004;8:67–8.Lash S. C., Williams C. P., Marsh C. S. et al. Acute sixth-nerve palsy after vincristine therapy. J APOS 2004;8:67–8.Naithani R., Dolai T. K., Kumar R. Bilateral vocal cord paralysis following treatment with vincristine. Indian Pediatr 2009;46(1):68–9.Naithani R., Dolai T. K., Kumar R. Bilateral vocal cord paralysis following treatment with vincristine. Indian Pediatr 2009;46(1):68–9.Ngamphaiboon N., Sweeney R., Wetzler M., Wang E. S. Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature. Leuk Res 2010;34(8):e194–6.Ngamphaiboon N., Sweeney R., Wetzler M., Wang E. S. Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature. Leuk Res 2010;34(8):e194–6.Мументалер М., Бассетти К., Дэтвайлер К. Дифференциальный диагноз в неврологии. М.: МЕДпресс- информ, 2010. С. 25. [Mumenthaler M., Bassetti C., Daetwyler C. Differential diagnosis in neurology. M.: MEDpress-inform, 2010. P. 25. (In Russ.)].Мументалер М., Бассетти К., Дэтвайлер К. Дифференциальный диагноз в неврологии. М.: МЕДпресс- информ, 2010. С. 25. [Mumenthaler M., Bassetti C., Daetwyler C. Differential diagnosis in neurology. M.: MEDpress-inform, 2010. P. 25. (In Russ.)].Drug formulary. Toronto: Cancer Care Ontario; 2009. http://www. cancercare.on.ca/.Drug formulary. Toronto: Cancer Care Ontario; 2009. http://www. cancercare.on.ca/.Akbayram S., Akgun C., Dogan M. et al. Use of pyridoxine and pyridostigmineAkbayram S., Akgun C., Dogan M. et al. Use of pyridoxine and pyridostigminein children with in vincristine induced neuropathy. Indian J Pediatr 2010;77(6):681–3.in children with in vincristine induced neuropathy. Indian J Pediatr 2010;77(6):681–3.Muller L., Kramm C. M., Tenenbaum T. et al. Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine. Pediatr Blood Cancer 2004;42(3):287–8.Muller L., Kramm C. M., Tenenbaum T. et al. Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine. Pediatr Blood Cancer 2004;42(3):287–8.Bhat K. G., Singhal V., Borker A. S. Successful treatment of vincristine-induced ptosis and polyneuropathy with pyridoxine and pyridostigmine in a child with acute lymphoblastic leukemia. PMC 2012;33(3):185–7.Bhat K. G., Singhal V., Borker A. S. Successful treatment of vincristine-induced ptosis and polyneuropathy with pyridoxine and pyridostigmine in a child with acute lymphoblastic leukemia. PMC 2012;33(3):185–7.

The authors declare that there are no conflicts of interest present.